Blockchain Registration Transaction Record

CEL-SCI Raises $7.2M in Public Offering to Advance Multikine

CEL-SCI completes $7.2M public offering for Multikine development, a neoadjuvant immunotherapy for head and neck cancer. Learn about CVM stock and the potential impact on cancer treatment.

This funding is crucial for CEL-SCI as it advances Multikine, a potential neoadjuvant therapy for head and neck cancer. If successful, Multikine could offer a novel treatment approach that primes the immune system before standard treatments, potentially improving survival rates for patients with squamous cell carcinoma. The capital raise demonstrates investor confidence and provides the resources needed to move toward clinical milestones, which could ultimately impact the standard of care in oncology.